Global Initiative for Asthma (GINA) Recommends the Use of Fractional Exhaled Nitric Oxide (FeNO) Monitoring for Difficult-to-Treat and Severe Asthma Management

Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that Fractional Exhaled Nitric Oxide (FeNO) monitoring is recommended in the latest Global Initiative for Asthma (GINA) guide, “Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients – Diagnosis and Management.” Lesen Sie weiter auf: Global Initiative for […]

…/Auszug